Tools

LEADER 05655nam 2200517 i 4500

001 ssj0001380185;

003 WaSeSS;

005 20260412090153.0;

006 m d ;

007 cr n ;

008 140821t20152015paua sb 001 0 eng d;

010 a| 2014033582;

020 a| 9780323287869 (hardcover : alk. paper);

020 a| 0323287867 (hardcover : alk. paper);

035 a| (WaSeSS)ssj0001380185;

042 a| pcc;

049 a| EREEa| NEHH;

050 10 a| QP751b| .C55 2015;

060 10 a| QY 465;

082 00 a| 616.1/22| 23;

245 00 a| Clinical lipidologyh| [electronic resource] :b| a companion to Braunwald's heart disease /c| [edited by] Christie M. Ballantyne, M.D., Professor of Medicine, Genetics, and Physiology, Chief, Section of Cardiovascular Research, Chief, Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas, Director, Center for Cardiovascular Disease Prevention, The Methodist DeBakey Heart and Vascular Center, Houston, Texas.;

250 a| 2nd edition.;

260 a| Philadelphia, PA :b| Elsevier Saunders,c| [2015];

300 a| xvi, 550 pages :b| color illustrations ;c| 29 cm;

500 a| Complemented by: Braunwald's heart disease / edited by Douglas L. Mann, Douglas P. Zipes, Peter Libby, Robert O. Bonow, Eugene Braunwald. 10th edition. [2015].;

504 a| Includes bibliographical references and index.;

505 0 a| Section I. Basic mechanisms -- 1. Human plasma lipoprotein metabolism -- 2. Regulation and clearance of apolipoprotein B-containing lipoproteins -- 3. Absorption and excretion of intestinal cholesterol and other sterols -- 4. High-density lipoprotein metabolism -- 5. Lipoproteins: mechanisms for atherogenesis and progression of atherothrombotic disease -- 6. Impact of rare and common genetic variants on lipoprotein metabolism -- 7. Lipoprotein oxidation: mechanisms and biotheranostic applications -- Section II. Risk assessment -- 8. Cholesterol: concentration, ratio, and particle number -- 9. High-density lipoprotein cholesterol and triglycerides in coronary heart disease risk assessment -- 10. Lipoprotein(a) -- 11. Clinical evaluation for genetic and secondary causes of dyslipidemia -- 12. Use of high-sensitivity C-reactive protein for risk assessment -- 13. Role of lipoprotein-associated phosphlipase A2 in vascular disease -- 14. Emerging assays -- 15. Imaging atherosclerosis for risk stratification by cardiac computed tomography or carotid ultrasound -- Section III. Therapy -- 16. Overview of general approach to management of elevated low-density lipoprotein cholesterol and mixed dyslipidemia, high triglycerides, and low high-density lipoprotein cholesterol -- 17. Treatment guidelines overview -- 18. Dietary patterns for the prevention and treatment of cardiovascular disease -- 19. Exercise and lipids -- 20. Weight loss -- 21. Statins -- 22. Bile acid sequestrants -- 23. Cholesterol absorption inhibitors -- 24. Niacin (nicotinic acid) -- 25. Fibrates -- 26. Omega-3 fatty acids -- 27. Combination therapy for dyslipidemia -- 28. Nutraceuticals and functional foods for cholesterol reduction -- 29. Evolving targets of therapy: cholesteryl ester transfer protein inhibition -- 30. Evolving targets of therapy: proprotein convertase subtilisin/kexin 9 inhibition -- 31. Evolving targets of therapy: inflammation as a method to predict and prevent cardiovascular events -- 32. Invasive imaging modalities and atherosclerosis: intravascular ultrasound -- 33. Noninvasive imaging modalities and atherosclerosis: the role of ultrasound -- 34. Noninvasive imaging modalities and atherosclerosis: the role of magnetic resonance imaging and positron emission tomography imaging -- 35. Special patient populations: diabetes and metabolic syndrome -- 36. Special patient population: women and elderly -- 37. Special patient populations: children and adolescents -- 38. Special patient populations: familial hypercholesterolemia and other severe hypercholesterolemias -- 39. Special patient populations: acute coronary syndrome -- 40. Special patient populations: transplant recipients -- 41. Special patient populations: chronic kidney disease -- 42. Special patient populations: lipid abnormalities in high-risk ethnic groups -- 43. Special patient populations: human immunodeficiency virus patients -- 44. Therapeutic targeting of high-density lipoprotein metabolism.;

506 a| Available only to authorized users.;

538 a| Mode of access: World Wide Web;

650 12 a| Lipoproteinsx| metabolism.=| ^A920040;

650 22 a| Cardiovascular Diseasesx| complications.=| ^A923070;

650 22 a| Dyslipidemias.=| ^A1004901;

650 22 a| Lipid Metabolism.=| ^A948279;

655 0 a| Electronic books.=| ^A491897;

700 1 a| Ballantyne, Christie M.=| ^A1320970;

730 0 a| Braunwald's heart disease.s| 10th ed.i| Complemented by (expression):?| UNAUTHORIZED;

856 40 z| Full text available from ScienceDirect eBooksu| https://go.openathens.net/redirector/ecu.edu?url=https%3A%2F%2Fwww.sciencedirect.com%2Fscience%2Fbook%2F9780323287869;

949 a| CLICK ON WEB ADDRESSw| ASISh| JOYNER188;

949 a| CLICK ON WEB ADDRESSw| ASISh| HSL77;

949 a| CLICK ON WEB ADDRESSw| ASISh| JMUSIC60;

596 a| 1 3 4;

998 a| 6717029;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 6717029-1001l| JNETm| JOYNERr| Ys| Yt| JNESSBKu| 4/14/2026x| EBOOKz| JERESOURCE;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 6717029-2001l| HSLELECm| HSLr| Ys| Yt| HEBKu| 4/14/2026x| EBOOKz| HERESOURCE;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 6717029-3001l| MNETm| JMUSICr| Ys| Yt| MNESSBKu| 4/14/2026x| EBOOKz| JERESOURCE;

Clinical lipidology a companion to Braunwald's heart disease / [edited by] Christie M. Ballantyne, M.D., Professor of Medicine, Genetics, and Physiology, Chief, Section of Cardiovascular Research, Chief, Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas, Director, Center for Cardiovascular Disease Prevention, The Methodist DeBakey Heart and Vascular Center, Houston, Texas.

Other author	Ballantyne, Christie M.
Format	Electronic
Edition	2nd edition.
Publication Info	Philadelphia, PA : Elsevier Saunders, [2015]
Description	xvi, 550 pages : color illustrations ; 29 cm
Supplemental Content	Full text available from ScienceDirect eBooks
Subjects	Lipoproteins--metabolism. Cardiovascular Diseases--complications. Dyslipidemias. Lipid Metabolism.

Contents	Section I. Basic mechanisms -- 1. Human plasma lipoprotein metabolism -- 2. Regulation and clearance of apolipoprotein B-containing lipoproteins -- 3. Absorption and excretion of intestinal cholesterol and other sterols -- 4. High-density lipoprotein metabolism -- 5. Lipoproteins: mechanisms for atherogenesis and progression of atherothrombotic disease -- 6. Impact of rare and common genetic variants on lipoprotein metabolism -- 7. Lipoprotein oxidation: mechanisms and biotheranostic applications -- Section II. Risk assessment -- 8. Cholesterol: concentration, ratio, and particle number -- 9. High-density lipoprotein cholesterol and triglycerides in coronary heart disease risk assessment -- 10. Lipoprotein(a) -- 11. Clinical evaluation for genetic and secondary causes of dyslipidemia -- 12. Use of high-sensitivity C-reactive protein for risk assessment -- 13. Role of lipoprotein-associated phosphlipase A2 in vascular disease -- 14. Emerging assays -- 15. Imaging atherosclerosis for risk stratification by cardiac computed tomography or carotid ultrasound -- Section III. Therapy -- 16. Overview of general approach to management of elevated low-density lipoprotein cholesterol and mixed dyslipidemia, high triglycerides, and low high-density lipoprotein cholesterol -- 17. Treatment guidelines overview -- 18. Dietary patterns for the prevention and treatment of cardiovascular disease -- 19. Exercise and lipids -- 20. Weight loss -- 21. Statins -- 22. Bile acid sequestrants -- 23. Cholesterol absorption inhibitors -- 24. Niacin (nicotinic acid) -- 25. Fibrates -- 26. Omega-3 fatty acids -- 27. Combination therapy for dyslipidemia -- 28. Nutraceuticals and functional foods for cholesterol reduction -- 29. Evolving targets of therapy: cholesteryl ester transfer protein inhibition -- 30. Evolving targets of therapy: proprotein convertase subtilisin/kexin 9 inhibition -- 31. Evolving targets of therapy: inflammation as a method to predict and prevent cardiovascular events -- 32. Invasive imaging modalities and atherosclerosis: intravascular ultrasound -- 33. Noninvasive imaging modalities and atherosclerosis: the role of ultrasound -- 34. Noninvasive imaging modalities and atherosclerosis: the role of magnetic resonance imaging and positron emission tomography imaging -- 35. Special patient populations: diabetes and metabolic syndrome -- 36. Special patient population: women and elderly -- 37. Special patient populations: children and adolescents -- 38. Special patient populations: familial hypercholesterolemia and other severe hypercholesterolemias -- 39. Special patient populations: acute coronary syndrome -- 40. Special patient populations: transplant recipients -- 41. Special patient populations: chronic kidney disease -- 42. Special patient populations: lipid abnormalities in high-risk ethnic groups -- 43. Special patient populations: human immunodeficiency virus patients -- 44. Therapeutic targeting of high-density lipoprotein metabolism.
General note	Complemented by: Braunwald's heart disease / edited by Douglas L. Mann, Douglas P. Zipes, Peter Libby, Robert O. Bonow, Eugene Braunwald. 10th edition. [2015].
Bibliography note	Includes bibliographical references and index.
Access restriction	Available only to authorized users.
Technical details	Mode of access: World Wide Web
Genre/form	Electronic books.
Other title	Braunwald's heart disease. 10th ed. Complemented by (expression):
LCCN	2014033582
ISBN	9780323287869 (hardcover : alk. paper)
ISBN	0323287867 (hardcover : alk. paper)

Availability

Library	Location	Call Number	Status	Item Actions
	Electronic Resources	Access Content Online	✔ Available

Click here for more information about this title

Availability